Main Menu

Press Releases

HistoIndex Presents Advancements in AI-powered Stain-free Tissue Imaging for NASH Clinical Trials at EASL Congress 2023

June 21, 2023

TANDEM study shows potential of HistoIndex SHG/TPE imaging and AI-based technology in evaluating the effects of combination therapy for NASH

June 15, 2023

HistoIndex SHG/TPE imaging and AI-based technology reveals dose-dependent effectiveness of Tropifexor for NASH patients in Nature Medicine

June 15, 2023

HistoIndex embarks on partnership with VCU’s Stravitz-Sanyal Institute for Liver Disease and Metabolic Health in the study of liver diseases

April 10, 2023

Appointment of Dr. David John Jeans CBE as HistoIndex’s Non-Executive Chairman

January 9, 2023

HistoIndex Stain-free AI-DP Reveals Treatment-induced Zonal Regression of Fibrosis Colocalized with Reduction in Steatosis & Hepatocyte Ballooning in FLIGHT-FXR NASH Clinical Trial

July 29, 2022

HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials

March 9, 2022

HistoIndex and Galecto to Collaborate on Galecto’s Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology

October 20, 2021

HistoIndex’s Stain-free AI-based Digital Pathology Incorporated as Secondary and Exploratory Efficacy Endpoints in Sagimet’s NASH FASCINATE-2 Phase 2b Clinical Trial

August 18, 2021

HistoIndex’s AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo

June 25, 2021

HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC)

January 24, 2021

HistoIndex’s AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China

May 24, 2020

qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Histopathological Features

November 9, 2019

HistoIndex Announces Global Partnerships to Expand AI-Based Digital Pathology Platform as a Drug Discovery Tool in Preclinical Studies for Nonalcoholic Steatohepatitis (NASH)

October 26, 2019

LITMUS – Progress towards diagnosing and better treating liver disease

August 20, 2019

HistoIndex and ILBS Launch Centre of Excellence in New Delhi for Advanced Diagnostics and Clinical Research on Nonalcoholic Steatohepatitis (NASH)

August 7, 2019

HistoIndex’s Second Harmonic Generation (SHG) Technology: A Potentially Important Tool Used In Madrigal’s Phase 2 Nonalcoholic Steatohepatitis (NASH) Clinical Trial

December 23, 2018

A Worldwide Effort to Defeat Nonalcoholic Steatohepatitis (NASH)

June 8, 2018

HistoIndex and CymaBay Therapeutics Team Up to Advance NASH Drug Development

May 18, 2018

HistoIndex Receives Frost & Sullivan 2017 Asia-Pacific Best Practices Award for Innovative Diagnostics in the Area of Nonalcoholic Steatohepatitis (NASH)

October 4, 2017

Connect with us

Linkedin Youtube

Pages

Locations

Singapore HQ
79 Ayer Rajah Crescent, #04-05
JTC Launchpad, Singapore 139955
Tel: +65 6774 4990

UK Branch
Queen Elizabeth University Hospital,
Imaging Centre of Excellence, L3-18, Langlands Drive, Glasgow G51 4LB,
United Kingdom
Tel: +44 0141 451 6800

China Subsidiary Office
Room 1001, Building 10
No. 188 Binkang Road, Hangzhou
Zhejiang 310051, China

© Histoindex Pte Ltd. All Rights Reserved. All logos and trademarks are the property of HistoIndex or their respective owners.